Details for Patent: 8,021,344
✉ Email this page to a colleague
Which drugs does patent 8,021,344 protect, and when does it expire?
Patent 8,021,344 protects AUVI-Q, EVZIO, and EVZIO (AUTOINJECTOR), and is included in three NDAs.
This patent has one hundred and six patent family members in fourteen countries.
Summary for Patent: 8,021,344
| Title: | Medicament delivery device configured to produce an audible output |
| Abstract: | Medicament delivery devices are described herein. In some embodiments, an apparatus includes a medicament delivery device and an electronic circuit system. The medicament delivery device includes a housing, a medicament container, and a medicament delivery member. The electronic circuit system is coupled to the housing and includes an audible output device and a cover. The housing of the medicament delivery device and the cover of the electronic circuit system collectively define an acoustic enclosure. The audible output device is configured to be disposed within the acoustic enclosure. |
| Inventor(s): | Eric S. Edwards, Evan T. Edwards, Mark J. Licata, Paul F. Meyers, David A. Weinzierl |
| Assignee: | EBAP Inc DBA STREAMLINE DESIGN , kaleo Inc |
| Application Number: | US12/180,708 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent 8,021,344
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-003 | Nov 17, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-002 | Aug 10, 2012 | BX | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Kaleo Inc | AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739-001 | Aug 10, 2012 | BX | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Kaleo Inc | EVZIO | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 205787-001 | Apr 3, 2014 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Kaleo Inc | EVZIO (AUTOINJECTOR) | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 209862-001 | Oct 19, 2016 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,021,344
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2004325202 | ⤷ Start Trial | |||
| Australia | 2006210865 | ⤷ Start Trial | |||
| Australia | 2007245139 | ⤷ Start Trial | |||
| Australia | 2009200841 | ⤷ Start Trial | |||
| Australia | 2009246525 | ⤷ Start Trial | |||
| Australia | 2012201481 | ⤷ Start Trial | |||
| Australia | 2015264857 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
